Pergamum appoints Jan Nilsson as Chief Marketing Officer
Stockholm, May 13, 2011. Pergamum has appointed Jan Nilsson as Chief Marketing Officer and as Managing Director of the LL-37 program – Pergamum’s program for wound healing in chronic leg ulcers. Jan Nilsson has previously held a number of executive leadership positions within international life science companies. Also, he has worked as an executive consultant and advisor for a number of smaller biotechs.
"Jan Nilsson will provide significant leadership capabilities to Pergamum. In his role as Chief Marketing Officer, he will strengthen our ability to design our development programs based on market and customer input. He will be able to transform our longterm research focus into specialist care products. Furthermore, Jan’s experience in both small molecules and biopharmaceuticals will be of great importance for the continued development of the company,” says Pergamum’s CEO Jonas Ekblom.
"I am really excited about joining Pergamum. I strongly believe in Pergamum’s strategy and focused ambitions to become a strong, international company within skin infections and wound healing. And – I believe Pergamum has great opportunities within to the area of therapeutic peptides," says Jan Nilsson.
Jan Nilsson will assume his position during the second quarter of 2011.
For more information, please contact:
Jonas Ekblom, CEO Phone: +46-8-524 89 100
Pergamum is a biopharmaceutical company specialized in the development of therapeutic peptides for treatment of skin infections and wounds. Within Pergamum, companies and projects are managed as fully integrated operating units with access to a core team of experienced professionals within drug development and business management. This model provides Pergamum with an attractive diversified product pipeline, while minimizing development cost and time-to-market and mitigating risk. Three programs are currently in clinical phase. www.pergamum.com